Friedman M A, Ogawa M, Carter S K, Sakurai Y, Kimura K, Hannigan J
Cancer. 1983 Nov 15;52(10):1771-7. doi: 10.1002/1097-0142(19831115)52:10<1771::aid-cncr2820521002>3.0.co;2-u.
A consortium of Northern California and Japanese investigators studied 142 patients with advanced gastric adenocarcinoma. Patients were randomized to one of two combination chemotherapy programs in each nation (one common therapy shared and one therapy unique to each nation). Median duration of survival ranged between 5 and 45 weeks, depending on performance status, extent of disease, and chemotherapy program. More importantly, there was considerable comparability with respect to toxicity and outcome between patients in the US and Japan. Overall median survival was 26 weeks for Japanese and 27 weeks for US patients. This study helps provide the basis for future comparative multinational trials.
北加利福尼亚和日本的研究人员组成的一个联合团队对142例晚期胃腺癌患者进行了研究。在每个国家，患者被随机分配到两种联合化疗方案中的一种（一种是两国共享的常见疗法，另一种是每个国家特有的疗法）。中位生存期在5至45周之间，具体取决于身体状况、疾病范围和化疗方案。更重要的是，美国和日本患者在毒性和治疗结果方面具有相当的可比性。日本患者的总体中位生存期为26周，美国患者为27周。这项研究有助于为未来的跨国比较试验提供基础。
